Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Prem Sobti

Oncology | Hematology
Carle Health System
Carle Health Care Incorporated
611 W Park St, 
Urbana, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients

Experienced in WT1-Related Wilms Tumor Syndromes
Carle Health System
Carle Health Care Incorporated
611 W Park St, 
Urbana, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Prem Sobti is an Oncologist and a Hematologist in Urbana, Illinois. Dr. Sobti is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Sobti is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MO
Hospital Affiliations
Kirby Medical Center
Carle Foundation Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CARLE HEALTH CARE INCORPORATED
611 W Park St, Urbana, IL 61801
Call: 888-712-2753
Other Locations
HOOPESTON COMMUNITY MEMORIAL HOSPITAL
2512 Hurst Dr, Suite 130, Mattoon, IL 61938
Call: 217-258-5900
CARLE HEALTH CARE INCORPORATED
200 Lerna Rd S, Mattoon, IL 61938
Call: 217-258-5900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma
A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: September 26, 2023
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Pankaj D. Kumar
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Pankaj D. Kumar
Hematology Oncology | Hematology | Oncology

Oncology-Hematology Associates Of Central Illinois P C

3105 Magory Dr, 
Bloomington, IL 
 (45.1 miles away)
309-662-2102
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pankaj Kumar is a Hematologist Oncology specialist and a Hematologist in Bloomington, Illinois. Dr. Kumar is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, Breast Cancer, and Aortic Valve Replacement.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Patrick L. Gomez
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Patrick L. Gomez
Hematology Oncology | Hematology | Oncology

Oncology-Hematology Associates Of Central Illinois P C

3105 Magory Dr, 
Bloomington, IL 
 (45.1 miles away)
309-662-2102
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Gomez is a Hematologist Oncology specialist and a Hematologist in Bloomington, Illinois. Dr. Gomez is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Iron Deficiency Anemia, Familial Colorectal Cancer, Severe Congenital Neutropenia, and Pleuropulmonary Blastoma. Dr. Gomez is currently accepting new patients.

Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Priyankkumar Patel
Hematology | Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Priyankkumar Patel
Hematology | Oncology

Carle Health Care Incorporated

611 W Park St, 
Urbana, IL 
 (0.1 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Priyankkumar Patel is a Hematologist and an Oncologist in Urbana, Illinois. Dr. Patel has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Plasmacytoma, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Familial Pancreatic Cancer.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sobti's expertise for a condition
ConditionClose
    • Distinguished
    • Chronic Lymphocytic Leukemia (CLL)
      Dr. Sobti is
      Distinguished
      . Learn about Chronic Lymphocytic Leukemia (CLL).
      See more Chronic Lymphocytic Leukemia (CLL) experts
    • Colorectal Cancer
      Dr. Sobti is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Sobti is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Lung Cancer
      Dr. Sobti is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Pleuropulmonary Blastoma
      Dr. Sobti is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Sobti is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Sobti is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Sobti is
      Advanced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Anemia
      Dr. Sobti is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Sobti is
      Advanced
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    • EGFR Positive Lung Cancer
      Dr. Sobti is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    View All 26 Advanced Conditions
    • Experienced
    • Acute Eosinophilic Pneumonia
      Dr. Sobti is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Sobti is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Sobti is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Sobti is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Adult Soft Tissue Sarcoma
      Dr. Sobti is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Sobti is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    View All 109 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved